[Clinical evaluation of penbutolol (Hoe 893d) (beta adrenergic blocker), alone and in combination with hydrochlorothiazide, in the treatment of arterial hypertension. II. Effect on plasma electrolytes, renal function, plasma renin and aldosterone activity and risk factors, including plasma lipids].
D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004573:Electrolytes / Q000097:blood; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007677:Kidney Function Tests; D008055:Lipids / Q000097:blood; D010394:Penbutolol / Q000008:administration & dosage / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D012306:Risk
D000959:Antihypertensive Agents; D004573:Electrolytes; D008055:Lipids; D011412:Propanolamines; D006852:Hydrochlorothiazide; D000450:Aldosterone; D010394:Penbutolol; D012083:Renin
Evaluación clńica del penbutolol (Hoe 893 d) (bloqueante betaadrenérgico), solo y en combinación con hidroclorotiacida, en el tratamiento de la hipertensión arterial. II: Efecto sobre los electrólitos plasmáticos, función renal, actividad de renina plasmática y aldosterona y factores de riesgo, incluyendo lípidos plasmáticos.